Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
Identifieur interne : 000F93 ( Istex/Corpus ); précédent : 000F92; suivant : 000F94Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
Auteurs : Céline Gagnon ; Baltazar Gomez-Mancilla ; Rudolf Markstein ; Paul J. Bédard ; Thérèse Di PaoloSource :
- Progress in Neuropsychopharmacology & Biological Psychiatry [ 0278-5846 ] ; 1995.
Abstract
1. 1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment. 2. 2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. 3. 3. Following MPTP, [3H]-SCH 23390 specific binding to D-1 receptors as well as [3H]-spiperone and [3H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [3H]-SKF 38393 binding to D-1 receptors tended to decrease. 4. 4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys. 5. 5. In the posterior striatum, both dopaminergic treatments decreased towards control values [3H]-SCH 23390, [3H]-spiperone and [3H]-N-n-propylnorapomorphine binding whereas they did not significantly change [3H]-SKF 38393 specific binding. [3H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243. 6. 6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.
Url:
DOI: 10.1016/0278-5846(95)00110-H
Links to Exploration step
ISTEX:7908F0DDDD71AB73353787948ED454A99EF7EB74Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title><author><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name><affiliation><mods:affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</mods:affiliation></affiliation></author><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><affiliation><mods:affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</mods:affiliation></affiliation></author><author><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name><affiliation><mods:affiliation>Department of Preclinical Research Sandoz, Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="J Bedard, Paul" sort="J Bedard, Paul" uniqKey="J Bedard P" first="Paul" last="J. Bédard">Paul J. Bédard</name><affiliation><mods:affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</mods:affiliation></affiliation></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><affiliation><mods:affiliation>Address all correspondence and reprint requests to: Dr Thérèse Di Paolo Department of Molecular Endocrinology CHUL Research Center 2705, Laurier boulevard, Ste-Foy Quebec, Canada, G1V 4G2 Telephone: (418) 654-2296 Fax: (418) 654-2761.</mods:affiliation></affiliation><affiliation><mods:affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7908F0DDDD71AB73353787948ED454A99EF7EB74</idno><date when="1995" year="1995">1995</date><idno type="doi">10.1016/0278-5846(95)00110-H</idno><idno type="url">https://api-v5.istex.fr/document/7908F0DDDD71AB73353787948ED454A99EF7EB74/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F93</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title><author><name sortKey="Gagnon, Celine" sort="Gagnon, Celine" uniqKey="Gagnon C" first="Céline" last="Gagnon">Céline Gagnon</name><affiliation><mods:affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</mods:affiliation></affiliation></author><author><name sortKey="Gomez Mancilla, Baltazar" sort="Gomez Mancilla, Baltazar" uniqKey="Gomez Mancilla B" first="Baltazar" last="Gomez-Mancilla">Baltazar Gomez-Mancilla</name><affiliation><mods:affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</mods:affiliation></affiliation></author><author><name sortKey="Markstein, Rudolf" sort="Markstein, Rudolf" uniqKey="Markstein R" first="Rudolf" last="Markstein">Rudolf Markstein</name><affiliation><mods:affiliation>Department of Preclinical Research Sandoz, Basel, Switzerland</mods:affiliation></affiliation></author><author><name sortKey="J Bedard, Paul" sort="J Bedard, Paul" uniqKey="J Bedard P" first="Paul" last="J. Bédard">Paul J. Bédard</name><affiliation><mods:affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</mods:affiliation></affiliation></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><affiliation><mods:affiliation>Address all correspondence and reprint requests to: Dr Thérèse Di Paolo Department of Molecular Endocrinology CHUL Research Center 2705, Laurier boulevard, Ste-Foy Quebec, Canada, G1V 4G2 Telephone: (418) 654-2296 Fax: (418) 654-2761.</mods:affiliation></affiliation><affiliation><mods:affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Progress in Neuropsychopharmacology & Biological Psychiatry</title><title level="j" type="abbrev">PNP</title><idno type="ISSN">0278-5846</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995">1995</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="667">667</biblScope><biblScope unit="page" to="676">676</biblScope></imprint><idno type="ISSN">0278-5846</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0278-5846</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">1. 1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment. 2. 2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. 3. 3. Following MPTP, [3H]-SCH 23390 specific binding to D-1 receptors as well as [3H]-spiperone and [3H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [3H]-SKF 38393 binding to D-1 receptors tended to decrease. 4. 4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys. 5. 5. In the posterior striatum, both dopaminergic treatments decreased towards control values [3H]-SCH 23390, [3H]-spiperone and [3H]-N-n-propylnorapomorphine binding whereas they did not significantly change [3H]-SKF 38393 specific binding. [3H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243. 6. 6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Céline Gagnon</name><affiliations><json:string>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</json:string></affiliations></json:item><json:item><name>Baltazar Gomez-Mancilla</name><affiliations><json:string>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</json:string></affiliations></json:item><json:item><name>Rudolf Markstein</name><affiliations><json:string>Department of Preclinical Research Sandoz, Basel, Switzerland</json:string></affiliations></json:item><json:item><name>Paul J. Bédard</name><affiliations><json:string>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</json:string></affiliations></json:item><json:item><name>Thérèse Di Paolo</name><affiliations><json:string>Address all correspondence and reprint requests to: Dr Thérèse Di Paolo Department of Molecular Endocrinology CHUL Research Center 2705, Laurier boulevard, Ste-Foy Quebec, Canada, G1V 4G2 Telephone: (418) 654-2296 Fax: (418) 654-2761.</json:string><json:string>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Bromocriptine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CY 208–243</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Dopamine D-1 receptor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine D-2 receptor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MPTP-monkeys</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CY 208–243 ((−)-4</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>6</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>6a</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>7</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>8</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>12β-hexahydro-7-methyl-indolo[4</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>3-ab] phenanthridine)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine (DA)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>1-3</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>4 dihydroxyphenylalanine (L-DOPA)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>N-methyl-4-phenyl-1</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>2</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>3</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>6-tetrahydropyridine (MPTP)</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>[3H]N-n-propylnorapomorphine ([3H]NPA)</value></json:item></subject><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>1. 1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment. 2. 2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. 3. 3. Following MPTP, [3H]-SCH 23390 specific binding to D-1 receptors as well as [3H]-spiperone and [3H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [3H]-SKF 38393 binding to D-1 receptors tended to decrease. 4. 4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys. 5. 5. In the posterior striatum, both dopaminergic treatments decreased towards control values [3H]-SCH 23390, [3H]-spiperone and [3H]-N-n-propylnorapomorphine binding whereas they did not significantly change [3H]-SKF 38393 specific binding. [3H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243. 6. 6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.</abstract><qualityIndicators><score>5.146</score><pdfWordCount>2590</pdfWordCount><pdfCharCount>19502</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>10</pdfPageCount><pdfPageSize>468 x 684 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>213</abstractWordCount><abstractCharCount>1517</abstractCharCount><keywordCount>20</keywordCount></qualityIndicators><title>Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title><pii><json:string>0278-5846(95)00110-H</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Progress in Neuropsychopharmacology & Biological Psychiatry</title><language><json:string>unknown</json:string></language><publicationDate>1995</publicationDate><issn><json:string>0278-5846</json:string></issn><pii><json:string>S0278-5846(00)X0008-5</json:string></pii><volume>19</volume><issue>4</issue><pages><first>667</first><last>676</last></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>social science</json:string><json:string>psychiatry</json:string><json:string>science</json:string><json:string>pharmacology & pharmacy</json:string><json:string>neurosciences</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>psychiatry</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string><json:string>toxicologie</json:string></inist></categories><publicationDate>1995</publicationDate><copyrightDate>1995</copyrightDate><doi><json:string>10.1016/0278-5846(95)00110-H</json:string></doi><id>7908F0DDDD71AB73353787948ED454A99EF7EB74</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/7908F0DDDD71AB73353787948ED454A99EF7EB74/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/7908F0DDDD71AB73353787948ED454A99EF7EB74/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/7908F0DDDD71AB73353787948ED454A99EF7EB74/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>ELSEVIER</p></availability><date>1995</date></publicationStmt><notesStmt><note type="content">Section title: Full length original paper experimental laboratory study</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title><author xml:id="author-0000"><persName><forename type="first">Céline</forename><surname>Gagnon</surname></persName><affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Baltazar</forename><surname>Gomez-Mancilla</surname></persName><affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Rudolf</forename><surname>Markstein</surname></persName><affiliation>Department of Preclinical Research Sandoz, Basel, Switzerland</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Paul</forename><surname>J. Bédard</surname></persName><affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Thérèse</forename><surname>Di Paolo</surname></persName><affiliation>Address all correspondence and reprint requests to: Dr Thérèse Di Paolo Department of Molecular Endocrinology CHUL Research Center 2705, Laurier boulevard, Ste-Foy Quebec, Canada, G1V 4G2 Telephone: (418) 654-2296 Fax: (418) 654-2761.</affiliation><affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</affiliation></author><idno type="istex">7908F0DDDD71AB73353787948ED454A99EF7EB74</idno><idno type="DOI">10.1016/0278-5846(95)00110-H</idno><idno type="PII">0278-5846(95)00110-H</idno></analytic><monogr><title level="j">Progress in Neuropsychopharmacology & Biological Psychiatry</title><title level="j" type="abbrev">PNP</title><idno type="pISSN">0278-5846</idno><idno type="PII">S0278-5846(00)X0008-5</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1995"></date><biblScope unit="volume">19</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="667">667</biblScope><biblScope unit="page" to="676">676</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1995</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>1. 1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment. 2. 2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. 3. 3. Following MPTP, [3H]-SCH 23390 specific binding to D-1 receptors as well as [3H]-spiperone and [3H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [3H]-SKF 38393 binding to D-1 receptors tended to decrease. 4. 4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys. 5. 5. In the posterior striatum, both dopaminergic treatments decreased towards control values [3H]-SCH 23390, [3H]-spiperone and [3H]-N-n-propylnorapomorphine binding whereas they did not significantly change [3H]-SKF 38393 specific binding. [3H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243. 6. 6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Bromocriptine</term></item><item><term>CY 208–243</term></item><item><term>Dopamine D-1 receptor</term></item><item><term>dopamine D-2 receptor</term></item><item><term>MPTP-monkeys</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Abbreviations</head><item><term>CY 208–243 ((−)-4</term></item><item><term>6</term></item><item><term>6a</term></item><item><term>7</term></item><item><term>8</term></item><item><term>12β-hexahydro-7-methyl-indolo[4</term></item><item><term>3-ab] phenanthridine)</term></item><item><term>dopamine (DA)</term></item><item><term>1-3</term></item><item><term>4 dihydroxyphenylalanine (L-DOPA)</term></item><item><term>N-methyl-4-phenyl-1</term></item><item><term>2</term></item><item><term>3</term></item><item><term>6-tetrahydropyridine (MPTP)</term></item><item><term>[3H]N-n-propylnorapomorphine ([3H]NPA)</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1995">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/7908F0DDDD71AB73353787948ED454A99EF7EB74/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>PNP</jid><aid>9500110H</aid><ce:pii>0278-5846(95)00110-H</ce:pii><ce:doi>10.1016/0278-5846(95)00110-H</ce:doi><ce:copyright type="unknown" year="1995"></ce:copyright></item-info><head><ce:dochead><ce:textfn>Full length original paper experimental laboratory study</ce:textfn></ce:dochead><ce:title>Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</ce:title><ce:author-group><ce:author><ce:given-name>Céline</ce:given-name><ce:surname>Gagnon</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Baltazar</ce:given-name><ce:surname>Gomez-Mancilla</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Rudolf</ce:given-name><ce:surname>Markstein</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>3</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Paul</ce:given-name><ce:surname>J. Bédard</ce:surname><ce:cross-ref refid="AFF2"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Thérèse</ce:given-name><ce:surname>Di Paolo</ce:surname><ce:cross-ref refid="COR1"><ce:sup>∗</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF1"><ce:sup>1</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>Department of Preclinical Research Sandoz, Basel, Switzerland</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>∗</ce:label><ce:text>Address all correspondence and reprint requests to: Dr Thérèse Di Paolo Department of Molecular Endocrinology CHUL Research Center 2705, Laurier boulevard, Ste-Foy Quebec, Canada, G1V 4G2 Telephone: (418) 654-2296 Fax: (418) 654-2761.</ce:text></ce:correspondence></ce:author-group><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para><ce:list><ce:list-item><ce:label>1.</ce:label><ce:para>1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment.</ce:para></ce:list-item><ce:list-item><ce:label>2.</ce:label><ce:para>2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia.</ce:para></ce:list-item><ce:list-item><ce:label>3.</ce:label><ce:para>3. Following MPTP, [<ce:sup loc="pre">3</ce:sup>H]-SCH 23390 specific binding to D-1 receptors as well as [<ce:sup loc="pre">3</ce:sup>H]-spiperone and [<ce:sup loc="pre">3</ce:sup>H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [<ce:sup loc="pre">3</ce:sup>H]-SKF 38393 binding to D-1 receptors tended to decrease.</ce:para></ce:list-item><ce:list-item><ce:label>4.</ce:label><ce:para>4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys.</ce:para></ce:list-item><ce:list-item><ce:label>5.</ce:label><ce:para>5. In the posterior striatum, both dopaminergic treatments decreased towards control values [<ce:sup loc="pre">3</ce:sup>H]-SCH 23390, [<ce:sup loc="pre">3</ce:sup>H]-spiperone and [<ce:sup loc="pre">3</ce:sup>H]-N-n-propylnorapomorphine binding whereas they did not significantly change [<ce:sup loc="pre">3</ce:sup>H]-SKF 38393 specific binding. [<ce:sup loc="pre">3</ce:sup>H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243.</ce:para></ce:list-item><ce:list-item><ce:label>6.</ce:label><ce:para>6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.</ce:para></ce:list-item></ce:list></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Bromocriptine</ce:text></ce:keyword><ce:keyword><ce:text>CY 208–243</ce:text></ce:keyword><ce:keyword><ce:text>Dopamine D-1 receptor</ce:text></ce:keyword><ce:keyword><ce:text>dopamine D-2 receptor</ce:text></ce:keyword><ce:keyword><ce:text>MPTP-monkeys</ce:text></ce:keyword></ce:keywords><ce:keywords class="abr"><ce:section-title>Abbreviations</ce:section-title><ce:keyword><ce:text>CY 208–243 ((−)-4</ce:text></ce:keyword><ce:keyword><ce:text>6</ce:text></ce:keyword><ce:keyword><ce:text>6a</ce:text></ce:keyword><ce:keyword><ce:text>7</ce:text></ce:keyword><ce:keyword><ce:text>8</ce:text></ce:keyword><ce:keyword><ce:text>12β-hexahydro-7-methyl-indolo[4</ce:text></ce:keyword><ce:keyword><ce:text>3-ab] phenanthridine)</ce:text></ce:keyword><ce:keyword><ce:text>dopamine (DA)</ce:text></ce:keyword><ce:keyword><ce:text>1-3</ce:text></ce:keyword><ce:keyword><ce:text>4 dihydroxyphenylalanine (L-DOPA)</ce:text></ce:keyword><ce:keyword><ce:text>N-methyl-4-phenyl-1</ce:text></ce:keyword><ce:keyword><ce:text>2</ce:text></ce:keyword><ce:keyword><ce:text>3</ce:text></ce:keyword><ce:keyword><ce:text>6-tetrahydropyridine (MPTP)</ce:text></ce:keyword><ce:keyword><ce:text>[<ce:sup loc="pre">3</ce:sup>H]N-n-propylnorapomorphine ([<ce:sup loc="pre">3</ce:sup>H]NPA)</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors</title></titleInfo><name type="personal"><namePart type="given">Céline</namePart><namePart type="family">Gagnon</namePart><affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Baltazar</namePart><namePart type="family">Gomez-Mancilla</namePart><affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rudolf</namePart><namePart type="family">Markstein</namePart><affiliation>Department of Preclinical Research Sandoz, Basel, Switzerland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul</namePart><namePart type="family">J. Bédard</namePart><affiliation>Centre de Recherche en Neurobiologie, Hôpital de l'Enfant-Jésus, Québec, and Department of Pharmacology, Laval University, Faculty of Medicine, Quebec, Qc, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thérèse</namePart><namePart type="family">Di Paolo</namePart><affiliation>Address all correspondence and reprint requests to: Dr Thérèse Di Paolo Department of Molecular Endocrinology CHUL Research Center 2705, Laurier boulevard, Ste-Foy Quebec, Canada, G1V 4G2 Telephone: (418) 654-2296 Fax: (418) 654-2761.</affiliation><affiliation>School of Pharmacy, Laval University, Quebec, and Department of Molecular Endocrinology, Laval University Medical Center, Ste-Foy, Qc, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1995</dateIssued><copyrightDate encoding="w3cdtf">1995</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">1. 1. Eleven monkeys were administered N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): eight were treated with bromocriptine for one week and then CY 208–243 (four monkeys) or saline (four monkeys) was added to the bromocriptine treatment. 2. 2. Addition of CY 208–243 increased the therapeutic response observed with the ergot alone without inducing dyskinesia. 3. 3. Following MPTP, [3H]-SCH 23390 specific binding to D-1 receptors as well as [3H]-spiperone and [3H]-N-n-propylnorapomorphine specific binding to D-2 receptors increased in posterior striatum compared to control animals, whereas [3H]-SKF 38393 binding to D-1 receptors tended to decrease. 4. 4. Dopamine receptor density was unchanged in anterior striatum of untreated MPTP-monkeys. 5. 5. In the posterior striatum, both dopaminergic treatments decreased towards control values [3H]-SCH 23390, [3H]-spiperone and [3H]-N-n-propylnorapomorphine binding whereas they did not significantly change [3H]-SKF 38393 specific binding. [3H]-SKF 38393 specific binding increased in anterior striatum of bromocriptine-treated MPTP-monkeys, compared to untreated MPTP-animals, and this increase was abolished in animals treated with bromocriptine + CY 208–243. 6. 6. The present study shows that in MPTP-monkeys, treated or not with DA agonists, the D1 and D2 receptor changes are concentrated in the posterior striatum and that denervation appears to cause a shift from the high to the low affinity agonist state of D1 receptors but not for the D2 subtype.</abstract><note type="content">Section title: Full length original paper experimental laboratory study</note><subject><genre>Keywords</genre><topic>Bromocriptine</topic><topic>CY 208–243</topic><topic>Dopamine D-1 receptor</topic><topic>dopamine D-2 receptor</topic><topic>MPTP-monkeys</topic></subject><subject><genre>Abbreviations</genre><topic>CY 208–243 ((−)-4</topic><topic>6</topic><topic>6a</topic><topic>7</topic><topic>8</topic><topic>12β-hexahydro-7-methyl-indolo[4</topic><topic>3-ab] phenanthridine)</topic><topic>dopamine (DA)</topic><topic>1-3</topic><topic>4 dihydroxyphenylalanine (L-DOPA)</topic><topic>N-methyl-4-phenyl-1</topic><topic>2</topic><topic>3</topic><topic>6-tetrahydropyridine (MPTP)</topic><topic>[3H]N-n-propylnorapomorphine ([3H]NPA)</topic></subject><relatedItem type="host"><titleInfo><title>Progress in Neuropsychopharmacology & Biological Psychiatry</title></titleInfo><titleInfo type="abbreviated"><title>PNP</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">199507</dateIssued></originInfo><identifier type="ISSN">0278-5846</identifier><identifier type="PII">S0278-5846(00)X0008-5</identifier><part><date>199507</date><detail type="volume"><number>19</number><caption>vol.</caption></detail><detail type="issue"><number>4</number><caption>no.</caption></detail><extent unit="issue pages"><start>541</start><end>711</end></extent><extent unit="pages"><start>667</start><end>676</end></extent></part></relatedItem><identifier type="istex">7908F0DDDD71AB73353787948ED454A99EF7EB74</identifier><identifier type="DOI">10.1016/0278-5846(95)00110-H</identifier><identifier type="PII">0278-5846(95)00110-H</identifier><recordInfo><recordContentSource>ELSEVIER</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000F93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:7908F0DDDD71AB73353787948ED454A99EF7EB74
|texte= Effect of adding the D-1 agonist CY 208–243 to chronic bromocriptine treatment of MPTP-monkeys: Regional changes of brain dopamine receptors
}}
| This area was generated with Dilib version V0.6.29. |  |